Back to results
US 2003/0073665 A1Published application
Formulations containing propofol and a sulfoalkyl ether cyclodextrin
AssigneeCydex, Inc.
InventorsDiane O. Thompson, Gerold L. Mosher
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCydex, Inc.
InventorsDiane O. Thompson, Gerold L. Mosher
Estimating the term…
An injectable formulation of a sedative hypnotic drug, such as the anesthetic drug propofol, that is pharmaceutically stable and demonstrates a reduced incidence of pain upon injection. The formulation of the present invention employs a sulfoalkyl ether cyclodextrin solubilizing and complexing excipient, such as CAPTISOL® cyclodextrin (sulfobutyl ether β-cyclodextrin) to form a true aqueous solution and not a suspension. This formulation minimizes the allergic response and microbial contamination issues typically associated with propofol parenteral formulations. The present formulation may also reduce pain on injection as compared to the known emulsion type propofol formulations. The liquid formulation can be sterile filtered unlike emulsion-type formulations of sedative hypnotics. The liquid formulation can be lyophilized or otherwise dried to yield a solid formulation.
A pharmaceutical liquid formulation comprising:
A pharmaceutical kit comprising:
A method of reducing the pain on injection associated with administration of propofol by injection or intravenous infusion, the method comprising the step of:
A method of administering propofol to a subject comprising the step of:
A reconstitutable solid pharmaceutical composition comprising:
Dependencies are inferred from the claim text.